Market news

To power Apple’s next phase, CEO John Ternus needs to raise Apple’s AI game.

Explore PVAL’s strong returns, attractive valuation and fundamentals vs CGDV, AVLV, SEIV, VFLO & IWD—see why it remains a Buy.

Dell stock plunges 11% after Barclays downgrade. Get key price levels, valuation metrics, and AI-server catalysts shaping DELL and tech sector moves—read...

The S&P 500 and Nasdaq tested key support. A hot inflation report didn't help.

A $100 billion Anthropic IPO could generate $700 million in bank fees. Find out which financial ETFs could benefit from a Wall Street IPO revival.

Silver's dramatic 2026 crash exposes a fierce divide: shrinking supply and forecasts of a rebound clash with Deutsche Bank's warning of an approaching surplus.

Hours before Apple and the ChatGPT maker were due to face off in court, a new allegation delayed the showdown

IonQ stock dropped 9.5% Wednesday. An equity raise isn’t wholly to blame. D-Wave, Quantinuum, and Rigetti Computing also saw substantial declines.

EWY ETF: South Korea memory sector exposure via Samsung/SK at cheap valuations.

I drove the 2026 Toyota 4Runner TRD Pro Wave Maker for a week. Here's why the rugged family SUV blew my mind.

Cantor’s C.J. Muse says ASML is effectively sold out through 2028, raises EPS estimates and keeps a €2,500 target, about 65% above the stock’s close.

Signs of stress in the high-yield “junk” bond market are rising, with recent borrowing tied to artificial intelligence falling under increased scrutiny.

Apple (AAPL) may launch Apple Intelligence in China this December with iOS 27.3—without the new Siri AI—after key regulatory steps.

The Hoge-Barrett Group establishes Captrust’s seventh office in its home state of North Carolina.

MORGANTOWN, W.Va., October 14, 2026--Infinity Natural Resources, Inc. ("Infinity" or the "Company") (NYSE: INR) today provided an update on the impact of derivative contracts for the third quarter 2026.

SentinelOne has climbed 64.0% year to date, so the obvious question now is whether that share price lines up with the cash flows its business can realistically generate. With the stock near US$24.01 after a mix of gains and pullbacks, the focus turns to what the cash flow math says rather than just the recent share price story. The 64.0% year to date return puts real weight on whether investors are paying a level that its future cash flows can ultimately support. The proposed US$1.25b zero...

Schwab Long-Term US Treasury ETF faces duration risk as long-term Treasury yields rise on inflation expectations, energy shocks & geopolitics. More on SCHQ.

The cloud computing industry is primed to benefit from the growing use of AI.

Weaker-than-expected results and a large regulatory fine weighed on shares.

Netflix is only laying off 6% of its workforce now. Here's a look back at the defining cuts for the company, in 2022 and 2001.

Barclays downgraded Dell, HPE, and NetApp on concerns that enterprise AI adoption is lagging.

DIVO employs a selective, actively managed covered-call strategy focused on large-cap, dividend-paying stocks. Read more on the fund here.

Our faith in the team of CEO Satya Nadella and CFO Amy Hood has paid off.

CoreWeave’s rising bond yields are rattling AI infrastructure stocks, including GE Vernova, Vertiv and Eaton.

You might get fewer “package delivery” scam texts now.

Cybercabs make up an increasing share of Tesla's robotaxi fleet.

Morgan Stanley (NYSE:MS) has outperformed the market over the past 10 years by 5.17% on an annualized basis producing an average annual return of 18.83%. Currently, Morgan Stanley has a market capitalization of $298.44

UnitedHealth's Q3 adjusted EPS surged 61% to $4.69 and raised its 2026 adjusted EPS outlook to at least $20.50. Click here to read this UNH stock update.

Lockheed Martin (LMT) upgraded to Buy as missile demand grows.

Detailed price information for Franco Nev Corp (FNV-N) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

GSK plc stock update: oncology pipeline momentum (Mo‑Rez phase 1), Cabenuva HIV data, Q2 results and 2026 phase 3 plans—click for this GSK update.